Does CAPMATINIB Cause Product dose omission issue? 76 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 76 reports of Product dose omission issue have been filed in association with CAPMATINIB (TABRECTA). This represents 3.3% of all adverse event reports for CAPMATINIB.
76
Reports of Product dose omission issue with CAPMATINIB
3.3%
of all CAPMATINIB reports
5
Deaths
15
Hospitalizations
How Dangerous Is Product dose omission issue From CAPMATINIB?
Of the 76 reports, 5 (6.6%) resulted in death, 15 (19.7%) required hospitalization, and 1 (1.3%) were considered life-threatening.
Is Product dose omission issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CAPMATINIB. However, 76 reports have been filed with the FAERS database.
What Other Side Effects Does CAPMATINIB Cause?
Death (411)
Peripheral swelling (283)
Fatigue (257)
Oedema peripheral (247)
Nausea (240)
Malignant neoplasm progression (178)
Dyspnoea (141)
Oedema (130)
Asthenia (113)
Non-small cell lung cancer (96)
What Other Drugs Cause Product dose omission issue?
DUPILUMAB (18,189)
USTEKINUMAB (9,405)
GUSELKUMAB (9,267)
LENALIDOMIDE (8,145)
MEPOLIZUMAB (5,873)
TOFACITINIB (5,646)
VOXELOTOR (5,122)
BELIMUMAB (4,671)
SECUKINUMAB (4,572)
APREMILAST (4,460)
Which CAPMATINIB Alternatives Have Lower Product dose omission issue Risk?
CAPMATINIB vs CAPREOMYCIN
CAPMATINIB vs CAPSAICIN
CAPMATINIB vs CAPTOPRIL
CAPMATINIB vs CARBAMAZEPINE
CAPMATINIB vs CARBETOCIN